ID   GEPH_HUMAN              Reviewed;         736 AA.
AC   Q9NQX3; Q96KU4; Q9H4E9; Q9P2G2;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   07-APR-2021, entry version 192.
DE   RecName: Full=Gephyrin {ECO:0000303|PubMed:10839351};
DE   Includes:
DE     RecName: Full=Molybdopterin adenylyltransferase;
DE              Short=MPT adenylyltransferase;
DE              EC=2.7.7.75 {ECO:0000305|PubMed:26613940};
DE     AltName: Full=Domain G;
DE   Includes:
DE     RecName: Full=Molybdopterin molybdenumtransferase;
DE              Short=MPT Mo-transferase;
DE              EC=2.10.1.1 {ECO:0000305|PubMed:22040219, ECO:0000305|PubMed:26613940};
DE     AltName: Full=Domain E;
GN   Name=GPHN {ECO:0000312|HGNC:HGNC:15465}; Synonyms=GPH, KIAA1385;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=10839351; DOI=10.1016/s0896-6273(00)81165-4;
RA   Butler M.H., Hayashi A., Okoshi N., Villmann C., Becker C.M., Feng G.,
RA   De Camilli P., Solimena M.;
RT   "Autoimmunity to gephyrin in Stiff-Man syndrome.";
RL   Neuron 26:307-312(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INVOLVEMENT IN MOCODC, AND PATHWAY.
RX   PubMed=11095995; DOI=10.1086/316941;
RA   Reiss J., Gross-Hardt S., Christensen E., Schmidt P., Mendel R.R.,
RA   Schwarz G.;
RT   "A mutation in the gene for the neurotransmitter receptor-clustering
RT   protein gephyrin causes a novel form of molybdenum cofactor deficiency.";
RL   Am. J. Hum. Genet. 68:208-213(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=11418245; DOI=10.1016/s0378-1119(01)00511-x;
RA   David-Watine B.;
RT   "The human gephyrin (GPHN) gene: structure, chromosome localization and
RT   expression in non-neuronal cells.";
RL   Gene 271:239-245(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI. The
RT   complete sequences of 150 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-266, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188 AND SER-194, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188 AND SER-194, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-188; SER-194; THR-198 AND
RP   SER-305, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, PALMITOYLATION AT CYS-212 AND
RP   CYS-284, AND MUTAGENESIS OF CYS-212 AND CYS-284.
RX   PubMed=25025157; DOI=10.1371/journal.pbio.1001908;
RA   Dejanovic B., Semtner M., Ebert S., Lamkemeyer T., Neuser F., Luescher B.,
RA   Meier J.C., Schwarz G.;
RT   "Palmitoylation of gephyrin controls receptor clustering and plasticity of
RT   GABAergic synapses.";
RL   PLoS Biol. 12:e1001908-e1001908(2014).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 1-181, AND SUBUNIT.
RX   PubMed=11554796; DOI=10.1006/jmbi.2001.4952;
RA   Schwarz G., Schrader N., Mendel R.R., Hecht H.-J., Schindelin H.;
RT   "Crystal structures of human gephyrin and plant Cnx1 G domains: comparative
RT   analysis and functional implications.";
RL   J. Mol. Biol. 312:405-418(2001).
RN   [16]
RP   VARIANT TYR-10, CHARACTERIZATION OF VARIANT TYR-10, AND INTERACTION WITH
RP   GLRB.
RX   PubMed=12684523; DOI=10.1074/jbc.m301070200;
RA   Rees M.I., Harvey K., Ward H., White J.H., Evans L., Duguid I.C.,
RA   Hsu C.-C., Coleman S.L., Miller J., Baer K., Waldvogel H.J., Gibbon F.,
RA   Smart T.G., Owen M.J., Harvey R.J., Snell R.G.;
RT   "Isoform heterogeneity of the human gephyrin gene (GPHN), binding domains
RT   to the glycine receptor, and mutation analysis in hyperekplexia.";
RL   J. Biol. Chem. 278:24688-24696(2003).
RN   [17]
RP   VARIANT MOCODC ALA-580, AND PATHWAY.
RX   PubMed=22040219; DOI=10.1111/j.1399-0004.2011.01709.x;
RA   Reiss J., Lenz U., Aquaviva-Bourdain C., Joriot-Chekaf S.,
RA   Mention-Mulliez K., Holder-Espinasse M.;
RT   "A GPHN point mutation leading to molybdenum cofactor deficiency.";
RL   Clin. Genet. 80:598-599(2011).
RN   [18]
RP   VARIANT MOCODC ASP-375, CHARACTERIZATION OF MOCODC VARIANTS ASP-375 AND
RP   ALA-580, INTERACTION WITH GABRA3 AND GLRB, SUBCELLULAR LOCATION, SUBUNIT,
RP   FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY.
RX   PubMed=26613940; DOI=10.15252/emmm.201505323;
RG   EuroEPINOMICS Dravet working group;
RA   Dejanovic B., Djemie T., Gruenewald N., Suls A., Kress V., Hetsch F.,
RA   Craiu D., Zemel M., Gormley P., Lal D., Myers C.T., Mefford H.C.,
RA   Palotie A., Helbig I., Meier J.C., De Jonghe P., Weckhuysen S., Schwarz G.;
RT   "Simultaneous impairment of neuronal and metabolic function of mutated
RT   gephyrin in a patient with epileptic encephalopathy.";
RL   EMBO Mol. Med. 7:1580-1594(2015).
CC   -!- FUNCTION: Microtubule-associated protein involved in membrane protein-
CC       cytoskeleton interactions. It is thought to anchor the inhibitory
CC       glycine receptor (GLYR) to subsynaptic microtubules (By similarity).
CC       Acts as a major instructive molecule at inhibitory synapses, where it
CC       also clusters GABA type A receptors (PubMed:25025157, PubMed:26613940).
CC       {ECO:0000250|UniProtKB:Q03555, ECO:0000269|PubMed:25025157,
CC       ECO:0000269|PubMed:26613940}.
CC   -!- FUNCTION: Has also a catalytic activity and catalyzes two steps in the
CC       biosynthesis of the molybdenum cofactor. In the first step,
CC       molybdopterin is adenylated. Subsequently, molybdate is inserted into
CC       adenylated molybdopterin and AMP is released.
CC       {ECO:0000269|PubMed:26613940}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H(+) + molybdopterin = adenylyl-molybdopterin +
CC         diphosphate; Xref=Rhea:RHEA:31331, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:58698,
CC         ChEBI:CHEBI:62727; EC=2.7.7.75;
CC         Evidence={ECO:0000305|PubMed:26613940};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:31332;
CC         Evidence={ECO:0000305|PubMed:26613940};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=adenylyl-molybdopterin + H(+) + molybdate = AMP + H2O + Mo-
CC         molybdopterin; Xref=Rhea:RHEA:35047, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:36264, ChEBI:CHEBI:62727,
CC         ChEBI:CHEBI:71302, ChEBI:CHEBI:456215; EC=2.10.1.1;
CC         Evidence={ECO:0000305|PubMed:22040219, ECO:0000305|PubMed:26613940};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35048;
CC         Evidence={ECO:0000305|PubMed:22040219, ECO:0000305|PubMed:26613940};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Inhibited by copper and tungsten. {ECO:0000250}.
CC   -!- PATHWAY: Cofactor biosynthesis; molybdopterin biosynthesis.
CC       {ECO:0000269|PubMed:11095995, ECO:0000269|PubMed:22040219,
CC       ECO:0000269|PubMed:26613940}.
CC   -!- SUBUNIT: Homotrimer, homodimer and homooligomer (PubMed:26613940).
CC       Interacts with GABARAP (By similarity). Interacts with SRGAP2 (via SH3
CC       domain) (By similarity). Interacts with GABRA3 (PubMed:26613940).
CC       Interacts with GLRB (PubMed:26613940, PubMed:12684523). GABRA3 and GLRB
CC       occupy overlapping binding sites (By similarity). Interacts with
CC       ARHGAP32; IQSEC3, INSYN1 and INSYN2A (By similarity).
CC       {ECO:0000250|UniProtKB:Q03555, ECO:0000250|UniProtKB:Q8BUV3,
CC       ECO:0000269|PubMed:12684523, ECO:0000269|PubMed:26613940}.
CC   -!- INTERACTION:
CC       Q9NQX3; P63167: DYNLL1; NbExp=2; IntAct=EBI-2371891, EBI-349105;
CC       Q9NQX3-2; Q8WV92: MITD1; NbExp=3; IntAct=EBI-11043087, EBI-2691489;
CC       Q9NQX3-2; P25786: PSMA1; NbExp=3; IntAct=EBI-11043087, EBI-359352;
CC   -!- SUBCELLULAR LOCATION: Cell junction, synapse, postsynaptic cell
CC       membrane {ECO:0000269|PubMed:25025157, ECO:0000269|PubMed:26613940};
CC       Lipid-anchor {ECO:0000269|PubMed:25025157}; Cytoplasmic side
CC       {ECO:0000305|PubMed:25025157}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q03555}; Lipid-anchor
CC       {ECO:0000250|UniProtKB:Q03555}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q03555}. Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:25025157}. Cytoplasm, cytoskeleton
CC       {ECO:0000250|UniProtKB:Q03555}. Cell projection, dendrite
CC       {ECO:0000269|PubMed:26613940}. Cell junction, synapse, postsynaptic
CC       density {ECO:0000250|UniProtKB:Q8BUV3}. Note=Cytoplasmic face of
CC       glycinergic postsynaptic membranes (By similarity). Forms clusters at
CC       synapses (PubMed:25025157). {ECO:0000250|UniProtKB:Q03555,
CC       ECO:0000269|PubMed:25025157}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQX3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQX3-2; Sequence=VSP_021769;
CC   -!- PTM: Palmitoylated (PubMed:25025157). Palmitoylation is stimulated by
CC       GABA type A receptors activity (By similarity). Palmitoylation by
CC       ZDHHC12 regulates clustering at synapses (PubMed:25025157).
CC       {ECO:0000250|UniProtKB:Q8BUV3, ECO:0000269|PubMed:25025157}.
CC   -!- DISEASE: Molybdenum cofactor deficiency, complementation group C
CC       (MOCODC) [MIM:615501]: A form of molybdenum cofactor deficiency, an
CC       autosomal recessive metabolic disorder leading to the pleiotropic loss
CC       of molybdoenzyme activities. It is clinically characterized by onset in
CC       infancy of poor feeding, intractable seizures, severe psychomotor
CC       retardation, and death in early childhood in most patients.
CC       {ECO:0000269|PubMed:11095995, ECO:0000269|PubMed:22040219,
CC       ECO:0000269|PubMed:26613940}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the MoaB/Mog family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the MoeA family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92623.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/GPHNID317.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ272033; CAC81240.1; -; mRNA.
DR   EMBL; AF272663; AAF81785.1; -; mRNA.
DR   EMBL; AJ272343; CAC10537.1; -; mRNA.
DR   EMBL; AB037806; BAA92623.1; ALT_INIT; mRNA.
DR   EMBL; BC030016; AAH30016.1; -; mRNA.
DR   CCDS; CCDS32103.1; -. [Q9NQX3-1]
DR   CCDS; CCDS9777.1; -. [Q9NQX3-2]
DR   RefSeq; NP_001019389.1; NM_001024218.1. [Q9NQX3-1]
DR   RefSeq; NP_065857.1; NM_020806.4. [Q9NQX3-2]
DR   PDB; 1JLJ; X-ray; 1.60 A; A/B/C=1-181.
DR   PDBsum; 1JLJ; -.
DR   SMR; Q9NQX3; -.
DR   BioGRID; 115537; 49.
DR   DIP; DIP-41076N; -.
DR   IntAct; Q9NQX3; 24.
DR   MINT; Q9NQX3; -.
DR   STRING; 9606.ENSP00000417901; -.
DR   DrugBank; DB01942; Formic acid.
DR   DrugBank; DB03366; Imidazole.
DR   DrugBank; DB03766; Propanoic acid.
DR   MoonDB; Q9NQX3; Curated.
DR   MoonProt; Q9NQX3; -.
DR   iPTMnet; Q9NQX3; -.
DR   PhosphoSitePlus; Q9NQX3; -.
DR   BioMuta; GPHN; -.
DR   DMDM; 13431554; -.
DR   EPD; Q9NQX3; -.
DR   jPOST; Q9NQX3; -.
DR   MassIVE; Q9NQX3; -.
DR   MaxQB; Q9NQX3; -.
DR   PaxDb; Q9NQX3; -.
DR   PeptideAtlas; Q9NQX3; -.
DR   PRIDE; Q9NQX3; -.
DR   ProteomicsDB; 82221; -. [Q9NQX3-1]
DR   ProteomicsDB; 82222; -. [Q9NQX3-2]
DR   ABCD; Q9NQX3; 8 sequenced antibodies.
DR   Antibodypedia; 144; 389 antibodies.
DR   DNASU; 10243; -.
DR   Ensembl; ENST00000315266; ENSP00000312771; ENSG00000171723. [Q9NQX3-1]
DR   Ensembl; ENST00000478722; ENSP00000417901; ENSG00000171723. [Q9NQX3-2]
DR   GeneID; 10243; -.
DR   KEGG; hsa:10243; -.
DR   UCSC; uc001xix.4; human. [Q9NQX3-1]
DR   CTD; 10243; -.
DR   DisGeNET; 10243; -.
DR   GeneCards; GPHN; -.
DR   HGNC; HGNC:15465; GPHN.
DR   HPA; ENSG00000171723; Low tissue specificity.
DR   MalaCards; GPHN; -.
DR   MIM; 603930; gene.
DR   MIM; 615501; phenotype.
DR   neXtProt; NX_Q9NQX3; -.
DR   OpenTargets; ENSG00000171723; -.
DR   Orphanet; 3197; Hereditary hyperekplexia.
DR   Orphanet; 308400; Sulfite oxidase deficiency due to molybdenum cofactor deficiency type C.
DR   PharmGKB; PA28840; -.
DR   VEuPathDB; HostDB:ENSG00000171723.15; -.
DR   eggNOG; KOG2371; Eukaryota.
DR   GeneTree; ENSGT00390000016577; -.
DR   HOGENOM; CLU_010186_2_2_1; -.
DR   InParanoid; Q9NQX3; -.
DR   OMA; KTLPHAC; -.
DR   OrthoDB; 1114121at2759; -.
DR   PhylomeDB; Q9NQX3; -.
DR   TreeFam; TF300902; -.
DR   BioCyc; MetaCyc:ENSG00000171723-MONOMER; -.
DR   PathwayCommons; Q9NQX3; -.
DR   Reactome; R-HSA-947581; Molybdenum cofactor biosynthesis.
DR   SIGNOR; Q9NQX3; -.
DR   UniPathway; UPA00344; -.
DR   BioGRID-ORCS; 10243; 3 hits in 992 CRISPR screens.
DR   ChiTaRS; GPHN; human.
DR   EvolutionaryTrace; Q9NQX3; -.
DR   GeneWiki; GPHN; -.
DR   GenomeRNAi; 10243; -.
DR   Pharos; Q9NQX3; Tbio.
DR   PRO; PR:Q9NQX3; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; Q9NQX3; protein.
DR   Bgee; ENSG00000171723; Expressed in corpus callosum and 216 other tissues.
DR   ExpressionAtlas; Q9NQX3; baseline and differential.
DR   Genevisible; Q9NQX3; HS.
DR   GO; GO:0099144; C:anchored component of synaptic membrane; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IEA:UniProtKB-SubCell.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; ISS:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:UniProtKB.
DR   GO; GO:0099572; C:postsynaptic specialization; IBA:GO_Central.
DR   GO; GO:0099634; C:postsynaptic specialization membrane; IEA:GOC.
DR   GO; GO:0097060; C:synaptic membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0061598; F:molybdopterin adenylyltransferase activity; IBA:GO_Central.
DR   GO; GO:0043546; F:molybdopterin cofactor binding; IDA:CAFA.
DR   GO; GO:0061599; F:molybdopterin molybdotransferase activity; IBA:GO_Central.
DR   GO; GO:0008940; F:nitrate reductase activity; IMP:CAFA.
DR   GO; GO:0007529; P:establishment of synaptic specificity at neuromuscular junction; IBA:GO_Central.
DR   GO; GO:0097112; P:gamma-aminobutyric acid receptor clustering; IDA:UniProtKB.
DR   GO; GO:0072579; P:glycine receptor clustering; IBA:GO_Central.
DR   GO; GO:0006777; P:Mo-molybdopterin cofactor biosynthetic process; IBA:GO_Central.
DR   GO; GO:0018315; P:molybdenum incorporation into molybdenum-molybdopterin complex; IBA:GO_Central.
DR   GO; GO:0032324; P:molybdopterin cofactor biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0098970; P:postsynaptic neurotransmitter receptor diffusion trapping; IBA:GO_Central.
DR   GO; GO:0010038; P:response to metal ion; IMP:CAFA.
DR   CDD; cd00887; MoeA; 1.
DR   CDD; cd00886; MogA_MoaB; 1.
DR   Gene3D; 2.40.340.10; -; 1.
DR   Gene3D; 3.40.980.10; -; 2.
DR   InterPro; IPR036425; MoaB/Mog-like_dom_sf.
DR   InterPro; IPR001453; MoaB/Mog_dom.
DR   InterPro; IPR008284; MoCF_biosynth_CS.
DR   InterPro; IPR038987; MoeA-like.
DR   InterPro; IPR005111; MoeA_C_domain_IV.
DR   InterPro; IPR036688; MoeA_C_domain_IV_sf.
DR   InterPro; IPR005110; MoeA_linker/N.
DR   InterPro; IPR036135; MoeA_linker/N_sf.
DR   PANTHER; PTHR10192; PTHR10192; 2.
DR   Pfam; PF00994; MoCF_biosynth; 2.
DR   Pfam; PF03454; MoeA_C; 1.
DR   Pfam; PF03453; MoeA_N; 1.
DR   SMART; SM00852; MoCF_biosynth; 2.
DR   SUPFAM; SSF53218; SSF53218; 2.
DR   SUPFAM; SSF63867; SSF63867; 1.
DR   SUPFAM; SSF63882; SSF63882; 1.
DR   TIGRFAMs; TIGR00177; molyb_syn; 2.
DR   PROSITE; PS01078; MOCF_BIOSYNTHESIS_1; 1.
DR   PROSITE; PS01079; MOCF_BIOSYNTHESIS_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Cell projection; Cytoplasm; Cytoskeleton; Disease variant;
KW   Lipoprotein; Magnesium; Membrane; Metal-binding; Molybdenum;
KW   Molybdenum cofactor biosynthesis; Multifunctional enzyme;
KW   Nucleotide-binding; Palmitate; Phosphoprotein; Postsynaptic cell membrane;
KW   Reference proteome; Synapse; Transferase.
FT   CHAIN           1..736
FT                   /note="Gephyrin"
FT                   /id="PRO_0000170964"
FT   REGION          14..166
FT                   /note="MPT Mo-transferase"
FT   REGION          140..316
FT                   /note="Interaction with GABARAP"
FT                   /evidence="ECO:0000250"
FT   REGION          326..736
FT                   /note="MPT adenylyltransferase"
FT   MOD_RES         188
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         194
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:24275569"
FT   MOD_RES         198
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         200
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUV3"
FT   MOD_RES         262
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUV3"
FT   MOD_RES         265
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUV3"
FT   MOD_RES         266
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243"
FT   MOD_RES         268
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUV3"
FT   MOD_RES         270
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BUV3"
FT   MOD_RES         305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   LIPID           212
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:25025157"
FT   LIPID           284
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:25025157"
FT   VAR_SEQ         243
FT                   /note="K -> KKHPFYTSPAVVMAHGEQPIPGLINYSHHSTDER (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:11418245,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_021769"
FT   VARIANT         10
FT                   /note="N -> Y (found in a patient with hyperekplexia;
FT                   unknown pathological significance; does not disrupt GLRB-
FT                   GPHN interactions; does not affect the structural lattices
FT                   formed by GPHN; dbSNP:rs121908539)"
FT                   /evidence="ECO:0000269|PubMed:12684523"
FT                   /id="VAR_044162"
FT   VARIANT         375
FT                   /note="G -> D (in MOCODC; patient phenotype resembling
FT                   Dravet syndrome; abolishes postsynaptic clustering of GPHN;
FT                   decreases cell-surface expression of GABA receptors;
FT                   impairs postsynaptic currents; catalytically inactive;
FT                   decreases binding affinity toward GABRA3; decreases binding
FT                   affinity toward GLRB)"
FT                   /evidence="ECO:0000269|PubMed:26613940"
FT                   /id="VAR_075626"
FT   VARIANT         580
FT                   /note="D -> A (in MOCODC; lacks molybdenum cofactor
FT                   synthesis activity; dbSNP:rs397518420)"
FT                   /evidence="ECO:0000269|PubMed:22040219,
FT                   ECO:0000269|PubMed:26613940"
FT                   /id="VAR_070275"
FT   MUTAGEN         212
FT                   /note="C->S: Decreased palmitoylation. Decreased clustering
FT                   at synaptic membranes. Decreased function in gamma-
FT                   aminobutyric acid receptor clustering. Loss of
FT                   palmitoylation, decreased clustering at synaptic membranes
FT                   and loss of function in gamma-aminobutyric acid receptor
FT                   clustering; when associated with S-284."
FT                   /evidence="ECO:0000269|PubMed:25025157"
FT   MUTAGEN         284
FT                   /note="C->S: Decreased palmitoylation. Decreased clustering
FT                   at synaptic membranes. Decreased function in gamma-
FT                   aminobutyric acid receptor clustering. Loss of
FT                   palmitoylation, decreased clustering at synaptic membranes
FT                   and loss of function in gamma-aminobutyric acid receptor
FT                   clustering; when associated with S-212."
FT                   /evidence="ECO:0000269|PubMed:25025157"
FT   CONFLICT        261
FT                   /note="A -> V (in Ref. 1; CAC81240)"
FT                   /evidence="ECO:0000305"
FT   STRAND          16..22
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           24..27
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           34..44
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   TURN            46..49
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   STRAND          52..59
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           63..75
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   STRAND          80..86
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   STRAND          89..91
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           96..103
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   STRAND          105..107
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           109..122
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           124..128
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   STRAND          133..136
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   STRAND          139..144
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           148..158
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           159..161
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           162..169
FT                   /evidence="ECO:0007744|PDB:1JLJ"
FT   HELIX           175..178
FT                   /evidence="ECO:0007744|PDB:1JLJ"
SQ   SEQUENCE   736 AA;  79748 MW;  E2BDA3AD3AB962C0 CRC64;
     MATEGMILTN HDHQIRVGVL TVSDSCFRNL AEDRSGINLK DLVQDPSLLG GTISAYKIVP
     DEIEEIKETL IDWCDEKELN LILTTGGTGF APRDVTPEAT KEVIEREAPG MALAMLMGSL
     NVTPLGMLSR PVCGIRGKTL IINLPGSKKG SQECFQFILP ALPHAIDLLR DAIVKVKEVH
     DELEDLPSPP PPLSPPPTTS PHKQTEDKGV QCEEEEEEKK DSGVASTEDS SSSHITAAAI
     AAKIPDSIIS RGVQVLPRDT ASLSTTPSES PRAQATSRLS TASCPTPKVQ SRCSSKENIL
     RASHSAVDIT KVARRHRMSP FPLTSMDKAF ITVLEMTPVL GTEIINYRDG MGRVLAQDVY
     AKDNLPPFPA SVKDGYAVRA ADGPGDRFII GESQAGEQPT QTVMPGQVMR VTTGAPIPCG
     ADAVVQVEDT ELIRESDDGT EELEVRILVQ ARPGQDIRPI GHDIKRGECV LAKGTHMGPS
     EIGLLATVGV TEVEVNKFPV VAVMSTGNEL LNPEDDLLPG KIRDSNRSTL LATIQEHGYP
     TINLGIVGDN PDDLLNALNE GISRADVIIT SGGVSMGEKD YLKQVLDIDL HAQIHFGRVF
     MKPGLPTTFA TLDIDGVRKI IFALPGNPVS AVVTCNLFVV PALRKMQGIL DPRPTIIKAR
     LSCDVKLDPR PEYHRCILTW HHQEPLPWAQ STGNQMSSRL MSMRSANGLL MLPPKTEQYV
     ELHKGEVVDV MVIGRL
//
